Sfoglia per Autore
Adaptive evolution of male accessory gland proteins involved in post-mating reproductive mechanisms of the african malaria mosquito Anopheles gambiae.
2010 Mancini, Emiliano; Tammaro, Federica; Baldini, F.; Serrao, A.; Rogers, D.; Sharakhov, I.; Catteruccia, F.; DELLA TORRE, Alessandra
MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients.
2011 Breccia, M; Federico, V; Loglisci, G; Latagliata, R; Santopietro, M; Salaroli, A; Serrao, A; Colafigli, G; Tafuri, Agostino; Alimena, Giuliana
Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase.
2011 Breccia, M; Girmenia, C; Latagliata, R; Loglisci, G; Santopietro, M; Federico, V; Petrucci, L; Serrao, A; Salaroli, A; Alimena, Giuliana
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
2011 Breccia, M; Santopietro, M; Cannella, L; Federico, V; Loglisci, G; Serrao, A; Petrucci, L; Salaroli, A; Nanni, M; Propris, Ms; Diverio, D; Alimena, Giuliana
The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS.
2011 Breccia, M; Loglisci, G; Finsinger, P; Salaroli, A; Serrao, A; Alimena, Giuliana
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.
2011 Breccia, M; Federico, V; Loglisci, G; Salaroli, A; Serrao, A; Alimena, Giuliana
Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib
2011 Giuseppina, Loglisci; Massimo, Breccia; Mauro, Nanni; Marco, Mancini; Rosa De Cuia, ; Laura, Cannella; Adriano, Salaroli; Vincenzo, Federico; Serrao, Alessandra; Loglisci, M. g.; Michelina, Santopietro; Alimena, Giuliana
Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences.
2011 Breccia, M; Loglisci, G; Cannella, L; Serrao, A; Colafigli, G; Salaroli, A; Alimena, Giuliana
Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes.
2012 Salaroli, A; Loglisci, G; Serrao, A; Alimena, Giuliana; Breccia, M.
Combination of azacitidine and ESA in myelodysplastic patients: The need for prospective studies
2012 Massimo, Breccia; Giuseppina, Loglisci; Adriano, Salaroli; Alessandra, Serrao; Luigi, Petrucci; Irene, Zacheo; Alimena, Giuliana
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials.
2012 Breccia, M; Loglisci, G; Salaroli, A; Serrao, A; Petrucci, L; Mancini, M; Alimena, Giuliana
Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia
2012 Laura, Cannella; Giuseppina, Loglisci; Mauro, Nanni; De Cuia, M. r.; Gioia, Colafigli; Adriano, Salaroli; Serrao, Alessandra; Alimena, Giuliana; Massimo, Breccia
Prognostic Features of Myelodysplastic Syndrome Patients Aged < 50 years: Update of a Single Institution Experience.
2012 Breccia, M; Finsinger, P; Loglisci, G; Santopietro, M; Salaroli, A; Serrao, A; Latagliata, R; Volpicelli, P; Petrucci, L; Nanni, M; Alimena, Giuliana
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response
2012 Breccia, Massimo; Giuseppina, Loglisci; Laura, Cannella; Paola, Finsinger; Marco, Mancini; Serrao, Alessandra; Michelina, Santopietro; Adriano, Salaroli; Alimena, Giuliana
Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients
2012 Breccia, Massimo; Giuseppina, Loglisci; Adriano, Salaroli; Paola, Finsinger; Serrao, Alessandra; Petrucci, Luigi; Alimena, Giuliana
Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index.
2012 Breccia, M; Loglisci, G; Salaroli, A; Serrao, A; Alimena, Giuliana
Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best?
2012 Breccia, M; Finsinger, P; Loglisci, G; Colafigli, G; Serrao, A; Salaroli, A; Petrucci, L; Alimena, Giuliana
MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
2012 M., Breccia; A., Salaroli; G., Loglisci; P., Finsinger; A., Serrao; Alimena, Giuliana
Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia.
2012 Breccia, M; Serrao, A; Salaroli, A; Loglisci, G; Zacheo, I; Alimena, Giuliana
The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line.
2012 Breccia, M; Finsinger, P; Loglisci, G; Latagliata, R; Mancini, M; Salaroli, A; Serrao, A; Zacheo, I; Alimena, Giuliana
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile